Zhengye Biotechnology Holding Limited Class A Ordinary Shares (ZYBT) is a publicly traded Healthcare sector company. As of November 12, 2026, ZYBT trades at $1.49 with a market cap of $72.03M and a P/E ratio of 0.00. ZYBT moved +0.00% today. Year to date, ZYBT is +29.13%; over the trailing twelve months it is -31.25%. Its 52-week range spans $0.62 to $14.30. Rallies surfaces ZYBT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Zhengye Biotechnology first-half revenue falls 18.3% as customer costs cut sales: Zhengye Biotechnology’s first-half 2026 revenue fell 18.3% to RMB 50.95 million as customers cut costs, while its net loss narrowed to RMB 22.16 million. Operating cash outflow widened to RMB 16.81 million as receivables and inventory weighed on working capital.
| Metric | Value |
|---|---|
| Price | $1.49 |
| Market Cap | $72.03M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $14.30 |
| 52-Week Low | $0.62 |
| Volume | 29.10K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
ZYBT analyst coverage data. Average price target: $0.00.